SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-99.1
Date Filed: 2025-11-13
Accession Number: 0001213900-25-109585
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025109585/ea026529201ex99-1_synergy.htm

Chunk 0 of 2
Word Count: 1497
Character Count: 9899

Document Content:

Exhibit 99.1

Synergy CHC Corp. Reports Third Quarter 2025
Financial Results and its Eleventh Consecutive Quarter of Profitability

WESTBROOK, Maine, November 13, 2025 –
Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company,
is announcing its financial results for the three months ended September 30, 2025.

“We are pleased to report our 11th
quarter of profitability and double-digit revenue growth, accompanied by over 300 basis points of gross margin expansion,” said
Jack Ross, CEO of Synergy CHC Corp. “We made meaningful progress across our strategic priorities by expanding retail authorizations
and distribution partnerships for our FOCUSfactor functional beverages and shots. Key partnerships with leading retailers, including Kroger
and Wakefern, are strengthening our reach across North America. Additionally, we completed a $4.4 million public offering in August, providing
us with added working capital to support continued growth and brand expansion. With this added flexibility, along with our retail and
distribution efforts, we’re well positioned for growth in the fourth quarter and beyond, which we believe will create meaningful
value for our shareholders.”

Third Quarter 2025 Financial Summary vs. Same
Year-Ago Period

●	Revenue of $8.0 million vs. $7.1 million.

●	Gross margin of 70.9% vs. 67.2%.

●	Income from operations of $1.28 million vs. $1.05
million.

●	Net income of $125.3 thousand vs. $783.6 thousand.

●	Earnings per share of $0.01 vs. $0.11.

●	EBITDA, a non-GAAP financial measure, was $1.31
million vs. $1.33 million.

●	Adjusted EBITDA, a non-GAAP financial measure,
was $1.52 million vs. $1.34 million.

●	Adjusted EBITDA per share, a non-GAAP financial
measure, was $0.15 vs. $0.18.

Recent Business Highlights

●	Synergy recently announced multiple new retail
and distribution wins for its FOCUSfactor supplements and beverages, including placements with Kroger and Wakefern, along with regional
partnerships with EG America, AlaBev and Atlantic Importing. These agreements expand FOCUSfactor’s U.S. footprint across grocery,
pharmacy and convenience channels.

●	On August 27, 2025, Synergy announced the completion
of its $4.4 million underwritten public offering of common stock, providing additional working capital to support continued growth initiatives.

●	On September 22, 2025, Synergy appointed former
Costco executive Teresa Thompson to the Board of Directors, strengthening the Company’s retail and consumer health expertise.

●	During the third quarter, the Company reduced
outstanding liabilities by $3.3 million.

●	Subsequent to quarter end, Synergy announced
that FOCUSfactor was named the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026 by Pharmacy Times, underscoring the brand’s
category leadership and continued consumer and professional trust.

Third Quarter 2025 Financial Results

Revenue in the third quarter of 2025 was $8.0
million, up 12.4% compared to $7.1 million in the third quarter of 2024.

Gross margin in the third quarter of 2025 was
70.9% compared to 67.2% in the third quarter of 2024. The increase was largely driven by a favorable shift in product mix.

Operating expenses in the third quarter of 2025
were $4.4 million, up 17.7% compared to $3.7 million in the third quarter of 2024. The increase was primarily driven by incremental costs
associated with being a public company and the added costs of launching the Company’s beverage division.

Income from operations for the third quarter of
2025 was $1.28 million, up 21.8% compared to $1.05 million in the third quarter of 2024. The increase in operating income was due to the
improvement in gross margin.

Net income in the third quarter of 2025 was $125.3
thousand compared to net income of $783.6 thousand in the third quarter of 2024.

Earnings per share in the third quarter of 2025
was $0.01 compared to $0.11 in the third quarter of 2024.

EBITDA (a non-GAAP financial measure) in the third
quarter of 2025 was $1.31 million compared to $1.33 million in the third quarter of 2024.

Adjusted EBITDA (a non-GAAP financial measure)
in the third quarter of 2025 was $1.52 million, up 13.4% compared to $1.34 million in the third quarter of 2024.

Adjusted EBITDA per share (a non-GAAP financial
measure) in the third quarter was $0.15 compared to $0.18 in the third quarter of 2024.

Balance Sheet and Cash Flow

As of September 30, 2025, Synergy had approximately
$1.0 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024.

As of September 30, 2025, Synergy had a working
capital surplus of $16.68 million, compared to a $1.12 million working capital deficit as of December 31, 2024.

As of September 30, 2025, Synergy had $2.1 million
in inventory, compared to $1.7 million in inventory as of December 31, 2024.

Cash used in operating activities for the nine
months ended September 30, 2025 was $3.21 million compared to cash used in operating activities of $1.38 million for the nine months ended
September 30, 2024. The increase was primarily attributable to a reduction in the Company’s liabilities and higher inventory investment
to launch its beverage division.

Non-GAAP Financial Measure Reconciliation:
EBITDA and Adjusted EBITDA

To assist financial statement users in an assessment
of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and
related events, as the Company believes that the non-GAAP information enhances investors’ overall understanding of our financial performance,
and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

Management believes EBITDA and Adjusted EBITDA
provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results
and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation
and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses and non-cash expenses.

The following table reconciles net income to EBITDA
and Adjusted EBITDA (in millions of US dollars):

3 Months ended September 30

Net income for the period $	0.13 $	0.78

Adjusted for:

Interest expense, net 1.16 0.71

Amortization of intangible assets 0.03 0.03

Tax benefit (0.01	) (0.19	)

EBITDA $	1.31 $	1.33

Foreign currency adjustment 0.02 0.01

Stock based compensation 0.19 -

Adjusted EBITDA $	1.52 $	1.34

Conference Call

In conjunction
with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on November 13, 2025, with the Company’s
Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be
available on the Investor Relations section
of Synergy’s website. To access the call by phone, please register here and
you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead
of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

About Synergy CHC Corp.

Synergy CHC Corp. develops and markets consumer
health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®,
a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the
U.S., Canada, and the U.K. through major retailers including Costco, Walmart, Amazon, BJ’s, and Walgreens, among others. The brand continues
to accelerate growth, penetrating new markets both domestically and internationally, with recent retail wins across mass, grocery, pharmacy,
convenience, and wholesale channels poised to drive meaningful gains in late 2025. Flat Tummy® complements Synergy’s
portfolio as a lifestyle brand focused on women’s wellness and weight management.

Forward Looking Statements

Certain statements contained in this press
release constitute “forward-looking statements,” including statements regarding brand expansion and growth initiatives. These
forward-looking statements represent Synergy’s expectations or beliefs concerning future events, and it is possible that the results described
in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which
are set forth in Synergy’s registration statement on Form S-1, as amended, many of which are outside of Synergy’s control, that could
cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as
of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible
for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and
other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy’s filings could
cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group

Cody Slach, Greg Robles

SNYR@gateway-grp.com

Synergy CHC Corp.

Condensed Consolidated Balance Sheets

September 30, 2025 December 31, 2024

(unaudited)

Assets

Current Assets

Cash and cash equivalents $	1,006,489 $	687,920

Restricted cash 100,000 100,000

Accounts receivable, net 6,812,649 5,321,037

Other receivables 2,182,755 1,999,637